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Renal failure is characterized by the progressive 
decline in the capacity of the kidneys to eliminate 
toxic solutes. In parallel, the “uremic syndrome” 
is depicted by a functional disturbance of enzymes, 
organelles, cells, and organs. This leads to an overall 
malaise that ultimately ends in coma and death un- 
less artificial kidney treatment (dialysis) is started 
(1). 
The current conception of dialysis is highly aspe- 
cific. Emphasis has been on the elimination of small, 
water-soluble compounds such as creatinine and 
urea; however, the toxicity of the latter substances 
is still debatable. Uremic biological fluids are in fact 
complex mixtures containing innumerable interfer- 
ing compounds that are the basis of the “uremic 
syndrome.” The uremic toxin probably does not 
exist (2). 
Despite several decades of study, the pathophysi- 
ology of the uremic syndrome remains i l l  defined. 
The possibilities in this domain have been improved 
recently by the introduction of new techniques for 
biochemical and biological evaluation and for sepa- 
ration and identification of the contents of complex 
biological fluids. The latter steps were made possible 
by the introduction of high-performance liquid chro- 
matography (HPLC). In our laboratory, a stepwise 
strategy has been developed whereby complex ure- 
mic mixtures (sera or ultrafiltrates) are fractionated 
in several fractions (eluates). By evaluating the ef- 
fect of uremic biological fluids on functional systems 
that are known to be disturbed in renal failure, we 
can pursue a fractionation of these biological fluids 
to identify the responsible compounds. This ap- 
proach has already enabled us to identify the sub- 
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stances responsible for changes in the functional 
capacity of biochemical systems with important 
clinical implications in end-stage renal failure: me- 
tabolization of calcitriol (relevant in treatment of 
renal bone disease); phagocytic polymorph meta- 
bolic function (relevant in susceptibility to infec- 
tion); and drug-protein binding (relevant in the effi- 
cacy and toxicity of drug treatment). 
This enabled us to better define the pathophysiol- 
ogy of these important clinical problems, which re- 
mained partly or entirely unresolved up to now. Sub- 
sequent efforts can be focused on a better definition 
and on improvement of the treatment of uremia by 
dialysis. 
Identification of the factors responsible for renal 
failure and improvement of the uremic condition 
have important clinical as well as socioeconomic 
implications (more than 1,000,000 patients are 
treated by renal replacement therapy worldwide). 
THE INFLUENCE OF UREMIC 
ULTRAFILTRATE ON CALCITRIOL 
METABOLISM 
Decreased production of calcitriol in renal failure 
is believed to be a major factor in the development 
of hyperparathyroidism, hypocalcemia, and renal 
osteodystrophy characteristic of chronic kidney dis- 
ease. Although loss of renal tissue is a primary cause 
of decreased calcitriol production in renal failure 
by a decrease in available la-hydroxylase, it  was 
demonstrated that uremic plasma ultrafiltrate also 
suppresses the production of calcitriol in normal rats 
(3). Uremic substances, not further defined, were 
also considered to play a major role in the changes 
in the metabolic clearance rate of calcitriol(3). Thus, 
uremic biological fluids contain factors that affect 
production and degradation of calcitriol. 
Our studies in this domain had as their main pur- 
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pose the attempt to define the factor(s) responsible 
for these defects. 
Uremic ultrafiltrate factors affect the metabolization 
of calcitriol 
To characterize the substances responsible for the 
suppression of the production and metabolic clear- 
ance of calcitriol in normal rats, uremic plasma ultra- 
filtrates were fractionated using HPLC (gradient of 
formic acid [pH 4.01 100% to methanol 80% in 52 
min) to study the effect of each fraction on calcitriol 
metabolism (3). Parameters of calcitriol metabolism 
were measured after an infusion of these fractions 
and of radiolabeled calcitriol to normal rats. The 
HPLC-elution patterns of the fractions with a sup- 
pressive effect suggest that at least two groups with 
distinguishable chemical characteristics are respon- 
sible: Fraction 4, containing small water-soluble 
compounds (mainly purines), and Fractions 6 to 13, 
containing mainly lipophilic, partially protein-bound 
substances. The molecular weight of the substances 
under evaluation, in view of the optimum separation 
expected for the HPLC technique used, is below 
2,000 daltons. One of the 13 fractions, Fraction 4, 
contains uric acid, xanthine, and hypoxanthine. In- 
fusion of subfractions of Fraction 4 markedly re- 
duced both the production and the metabolization 
of calcitriol. 
We conclude from this study that both the produc- 
tion and the degradation of calcitriol are influenced 
by solutes retained in uremic sera and ultrafiltrate. 
The previously held belief that such metabolic 
changes, especially in production of calcitriol, are 
due solely to a decrease in renal mass is contra- 
dicted. At least two groups of substances are respon- 
sible. One of these may be related to the purines; 
the other group is less well defined but is character- 
ized by an elution time in the second half of the 
HPLC system used, which suggests larger molecular 
weight, partial lipophilicity and/or hydrophobicity, 
and/or substantial protein binding. 
Purine derivatives influence calcitriol 
metabolization in rats 
The following study checks the relation suggested 
above between retention of purines in renal failure 
and suppression of metabolic production and clear- 
ance rate of calcitriol (4). Therefore, calcitriol me- 
tabolism was evaluated with or without the infusion 
of purines to healthy rats (4). The calcitriol produc- 
tion rate and clearance were significantly reduced 
after infusion of either theophylline (1 mg/h) or so- 
dium urate (0.5 mg/h) compared with those in con- 
trol rats infused with normal saline. Renal la-hy- 
droxygenase activity of kidney homogenate was sig- 
nificantly inhibited in rats infused with theophylline 
and urate. Administration of the purines uric acid 
and theophylline causes a decrease in plasma 
calcitriol concentration in view of the more im- 
portant decrease in production than in degradation. 
We conclude from this study that purine deriva- 
tives suppress calcitriol synthesis. These data thus 
confirm the “toxic” interference of the purines with 
calcitriol metabolization, especially for uric acid, 
which in general and despite repeated study has al- 
ways been considered as a nontoxic uremic solute. 
Uric acid levels inversely related to plasma calcitriol 
in patients with chronic renal failure 
In view of the finding of a decrease of calcitriol 
levels with increasing uric acid concentrations in 
normal rats, the effect of a decrease of uric acid 
levels of patients in end-stage renal failure was stud- 
ied (5) .  After I week of treatment with allopurinol, 
300 mg daily, plasma uric acid decreased signifi- 
cantly. The plasma concentration of calcitriol, how- 
ever, rose in each patient. Allopurinol per se had 
no effect on calcitriol metabolism. 
Administration of allopurinol suppresses plasma 
uric acid and increases plasma calcitriol in patients 
with chronic renal failure. Thus, uremia and hyper- 
uricemia could reduce the biological action of 
calcitriol on subsequent metabolic processes in pa- 
tients with renal failure, and the implications of these 
findings may go beyond the scope of the mere effect 
of uric acid on calcitriol metabolism alone (e.g., ef- 
fect of calcitriol on parathormone synthesis and on 
bone metabolism). Therefore, the use of allopurinol 
in the prevention of renal osteodystrophy in chronic 
renal failure should be further investigated. 
PHAGOCYTE METABOLIC ACTIVITY 
Infection is a frequent complication and a major 
cause of death among patients with end-stage renal 
failure. Polymorphonuclear phagocytes are im- 
portant in host defense mainly because of bacterial 
destruction by NADPH-oxidase-related free radical 
production following phagocytosis. Studies were un- 
dertaken to evaluate the leukocyte response to stim- 
uli by an evaluation of the glycolytic activity, in 
which the CO, production by the hexose monophos- 
phate shunt (HMS) in the energy delivery to NAD 
(P)H-oxidase is measured, and by estimations of 
production of free radical species. 
Prospective cross-sectional study in a population 
with renal failure 
The leukocyte response to phagocytic challenge 
was assessed in uremic and hemodialysis patients 
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in a prospective cross-sectional study (6). Using la- 
tex and zymosan as phagocytic challenge, the utili- 
zation of glucose- 1 -I4C and the generation of reactive 
oxygen species were measured in these patients. In 
uremic, non-dialysis-dependent patients, the re- 
sponse to phagocytosis was significantly reduced 
when serum creatinine exceeded 6 mg/dl, and prior 
to initiation of dialysis, it was less than half that of 
patients with normal renal function. In maintenance 
dialysis patients, despite enhanced elimination of 
uremic solutes, a similar suppression is observed. 
This decreased response to phagocytic stimulus 
could be used as a predictor of hospitalization for 
infectious reasons, especially overt bacteremias, as 
patients developing major infection necessitating 
hospitalization had significantly lower response. In 
a prospective study of 15 patients initiated on dial- 
ysis, the metabolic response of their leukocytes was 
assessed sequentially, and complement-activating 
Cuprophan membranes were compared with non- 
complement-activating polysulfone. The choice of 
the Cuprophan membrane was inspired by the find- 
ing that this dialysis membrane induces activation 
of complement factors: the question that arises then 
is whether this activation leaves the polymorphs 
with the ability to cope with further “natural stim- 
uli” once this prestimulation has taken place. 
In 8 patients, initiation of dialysis with the comple- 
ment-activating Cuprophan membrane led to a fur- 
ther decline (60%) in metabolic response to phagocy- 
tosis at the end of 4 weeks of dialysis compared with 
that before initiation of dialysis; however, in 7 other 
patients on dialysis with non-complement-activat- 
ing membranes, this decline was largely attenuated. 
Prospective crossover studies with fluorescence 
analysis in response to dichlorofluorescein-diacetate 
(a molecule that becomes fluorescent upon contact 
with oxygen-reactive species) and flow cytometry 
corroborated these findings. 
We conclude that there is in renal failure a pro- 
found disturbance in polymorph metabolic activity 
in response to phagocytosis. This disturbance is mul- 
tifactorial and is related to the progressive develop- 
ment of the uremic status as well as to the start of 
hemodialysis treatment. In relation to hemodialysis, 
the progressive functional decline is more profound 
in patients treated with complement-activating Cu- 
prophan than in those treated with non-comple- 
ment-activating polysulfone. These changes are cor- 
related to the hospitalization rate for major infection. 
The risk of host-defense disturbances in the phago- 
cytic immune system and the subsequent risk of 
infection thus increase with advancing uremia and 
with the use of the Cuprophan membrane. 
Acute effects of hemodialysis on 
phagocytic response 
In a second study, an in vivo and in vitro evalua- 
tion was undertaken comparing healthy control sub- 
jects and dialyzed renal failure patients and evaluat- 
ing the polymorph metabolic response to five 
different stimuli with different pathways for activa- 
tion of polymorphonuclear function: latex, zymo- 
san, Staphylococcus aureus, phorbol myristic acid, 
and f-Met-Leu-Phen (7). Our results show a marked 
and parallel inhibition in the response to these five 
stimuli in predialysis samples. This response is fur- 
ther suppressed after 15 min of Cuprophan dialysis 
for all stimuli ( -  40 to - 94%) except phorbol niyris- 
tic acid. Polymorphonuclear response remains intact 
during dialysis with non-complement-activating di- 
alyzers. In vitro experiments confirm decreased 
polymorphonuclear glycolytic activity after the sus- 
pension of Cuprophan fragments in normal whole 
blood. 
This study confirms the impairment of polymor- 
phonuclear cell energy delivery to NADPH-oxidase 
in patients with end-stage renal failure. The impaired 
response to various stimuli is different in predialysis 
blood samples and samples collected during Cupro- 
phan dialysis, so the inhibition observed in these 
two different conditions may be related to different 
mechanisms. 
Effect of uremic biological fluids on 
polymorph function 
In view of the progressive decline of polymorph 
NAD(P)H-related glycolysis during advancing ure- 
mia, it was evaluated whether this effect could be 
attributed to a compound (or compounds) retained in 
uremic biological fluids. Therefore, isolated normal 
and uremic polymorphs were suspended in normal 
and uremic plasma in a matched crossover study 
evaluating polymorph glycolytic activity in response 
to latex, zymosan, and S. aureus. An optimal re- 
sponse was obtained when normal cells were sus- 
pended in normal plasma whereas the response was 
minimal when uremic cells were suspended in ure- 
mic plasma (8). The responses of normal cells in 
uremic plasma and of uremic cells in normal plasma 
were intermediate. These data indicate that uremic 
plasma suppresses polymorph metabolism. Uremic 
ultrafiltrate caused a similar suppression. 
Effect of recombinant erythropoietin on polymorph 
metabolic capacity 
Erythropoietin has recently been introduced for 
the treatment of uremic anemia. In theory, only ef- 
fects on the erythroid cell line can be expected. To 
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evaluate the influence of erythropoietin on granulo- 
cyte function, a double-blind, randomized, placebo- 
controlled study was undertaken in 22 patients on 
maintenance hemodialysis (9). A marked and pro- 
gressive improvement was observed after a mean 
treatment period of 4 months. A significant correla- 
tion between hematocrit and I4CO2 production was 
observed in the erythropoietin-treated group. No 
such correlation was found with serum ferritin. 
The depressed phagocyte glycolytic activity of 
hemodialyzed uremic patients is normalized during 
correction of anemia by erythropoietin. This may 
be attributed to a better metabolic condition. Since 
in the present study no major changes in serum ferri- 
tin were obtained and the improvement was not cor- 
related to serum ferritin but only to hematocrit, re- 
duction of body iron stores may be a less important 
contributing factor. 
DRUG-PROTEIN BINDING 
A better understanding of the factors influencing 
the protein binding of drugs during renal failure has 
implications in the field of efficacy and toxicity of 
drug treatment as only free drugs can be considered 
to be pharmacologically active. In addition, drug- 
protein binding in renal failure is possibly decreased 
by not fully defined organic acid compounds. These 
organic acids interfering with drug-protein binding 
reportedly will alter the accumulation of other or- 
ganic acids in specific organs (e.g., the brain) as well 
as in the entire body; in addition, they widen the 
“anion gap,” which further adds to their toxic im- 
pact. Thus, inhibition of protein binding and failure 
of organic anion transport may be related to each 
other. 
Screening evaluation of patients with chronic 
renal failure 
In a first study, changes of the protein-binding 
properties of 9 drugs were evaluated by an ultrafil- 
tration technique (Centrifree) that indicates the frac- 
tion of free versus total radioactive drug in plasma 
solution after the ultrafiltration maneuver (10). In 
addition, theophylline and phenytoin, two drugs 
with the most substantial and progressive decrease 
in protein binding, were further studied by HPLC 
fractions of ultrafiltrate of normal and uremic serum 
in an attempt to identify substances causing inhibi- 
tion of drug-protein binding. Ultrafiltrate obtained 
during a hemofiltration session inhibited protein 
binding of theophylline and phenytoin in a dose- 
dependent way. After separation of this ultrafiltrate 
by HPLC, it appeared that for both theophylline and 
phenytoin at  least a part of this inhibitory activity 
corresponded to the elution zone of hippuric acid. 
For theophylline, two other inhibitory zones were 
further recognized: one corresponding to the elution 
zone of NaCl and one in which the responsible sub- 
stance remained unidentified. Hippuric acid in solu- 
tion inhibited protein binding of theophylline and 
phenytoin in a dose-dependent way. 
In conclusion, protein binding of several drugs 
currently used in the treatment of renal failure is 
affected in parallel with renal function, which might 
alter the effectiveness of the drugs. Hippuric acid 
appears to play an important role in the protein- 
binding defect of theophylline and phenytoin. 
Comparative studies of deproteinization methods 
Studies of factors affecting drug-protein binding 
based on ultrafiltrate have the disadvantage that by 
definition the heaviest protein binders are omitted 
from analysis. In addition, in our former analysis, 
HPLC fractionation was arrested at 30 min (i.e., at 
a S O  : S O  formate : methanol gradient) whereas the 
bulk of protein-bound substrate can be expected to 
be eluted more to the right on these chromatograms 
(i.e., for an eluate composition with more than 50% 
methanol). We therefore decided to repeat the same 
study as described above but with deproteinized ure- 
mic sera and with more extended chromatograms. 
We found, however, no reliable published data on 
the ligand yield of different currently used depro- 
teinization methods. Therefore, ligand extraction 
achieved after 12 different deproteinization methods 
was evaluated by comparison of ultraviolet-ab- 
sorbing peaks on high-performance liquid chromato- 
grams of uremic serum after deproteinization or ul- 
trafiltration (1 I ) .  In a first comparison, the number 
of peaks recovered and the number of significant 
peaks increasing by at least 25% in height after de- 
proteinization were markedly higher with the heat 
denaturation, acetonitrile extraction, trichloroacetic 
acid, bilirubin displacement, and acid precipitation/ 
acetonitrile extraction methods. A more detailed 
comparison of the effects of these S methods on the 
calculated protein binding of 14 peaks showed that 
the yield differed from method to method and from 
peak to peak and that the highest ligand extraction 
or yield resulted from the heat denaturation method. 
In conclusion, the yield of deproteinized ligand 
and the estimated protein binding of ligands differs 
with the deproteinization method used. More atten- 
tion should be paid to the specific deproteinization 
methods used in studies of uremic ligand extraction. 
The use of more than one deproteinization method 
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for studies of drug and ligand protein binding in 
uremia should enhance the reliability of the results. 
Influence of deproteinized serum samples on 
theophylline-protein binding 
Starting from this experience, we evaluated 
whether deproteinized uremic serum yielded more 
important inhibition of theophylline’s I4C protein 
binding compared with uremic ultrafiltrate. Two de- 
proteinization methods were evaluated: heat dena- 
turation and acetonitrile extraction (12). The addi- 
tion of 0.1 to 1.5 ml of lyophilized deproteinized 
uremic serum resulted in a more important decrease 
in theophylline-protein binding than did uremic ul- 
trafi I trate . 
In conclusion, theophylline-protein binding is sup- 
pressed more importantly by deproteinized uremic 
serum than by uremic ultrafiltrate. 
IMPLICATIONS IN THE DOMAIN OF 
HEMODIALYSIS 
Validity of urea and other markers 
of dialysis efficiency 
To appreciate the validity of azotemic markers 
as an index for intradialytic solute concentration 
changes, 8 solutes (pseudo-uridine, PS; xanthine, 
XA; hypoxanthine, HX; peak 4, P4; peak 5, P5; 
p-OH hippuric acid, PH; indoxyl sulfate, IS; and 
hippuric acid, HA) were compared to 5 classic azo- 
temic markers (urea, UR; creatinine, CR; uric acid, 
UA; phosphate, P; and potassium, K) (13). Concen- 
tration was determined by reversed-phase HPLC 
coupled to UV adsorption or by photometric analy- 
sis. Regression analysis revealed a significant in- 
termutual correlation (p < lo-’) for a cluster of 7 
compounds including urea as a classic parameter of 
dialysis adequacy as well as PS, UA, P4, P5, PH, 
and CR. The behavior of hippuric acid (HA) was 
specific in that its changes in concentration before 
and after dialysis correlated with this cluster of 7 
but also with IS, HX, and K,  as well as with the 
overall group of nonidentified UV-absorbing HPLC 
peaks accumulating in uremia. Solute concentration 
changes were different in two differing blood purifi- 
cation strategies, namely hemodialysis and hemodi- 
afiltration, for hippuric acid and p-OH hippuric acid 
but not for urea and creatinine. 
We conclude that urea is only partially representa- 
tive as a marker of the dialytic concentration 
changes of other retention compounds and that alter- 
native markers such as hippurate, measured either 
by colorimetry or by HPLC peak height analysis 
(14), should be considered. This is especially im- 
portant in view of our findings of the interference 
of several solutes with biological systems, many of 
which have a different intradialytic behavior than 
urea. Therefore, an optimum solute elimination 
should be pursued, not only of the water-soluble, 
urea-like compounds but also of the partially lipo- 
philic, larger compounds-mainly organic acids. 
These data further suggest that it is of value to 
introduce a marker of uremic solute retention in 
addition to urea to account for renal-function-re- 
lated, “organic-acid-like’’ compounds that are elimi- 
nated by renal tubular excretion in dialyzed patients. 
The hippurates may serve this purpose. 
CONCLUSION 
These data shed new light on the understanding 
and treatment of the uremic syndrome. Uremic in- 
toxication is a complex, multifactorial problem. Sev- 
eral different metabolic systems are affected. The 
disturbances in metabolic functions are reflected in 
clinical problems (e.g., phagocytosis vs. infection 
risk, metabolization of calcitriol vs. osteogenesis, 
drug-protein binding vs. therapeutic efficacy). The 
responsible solutes depend on the metabolic system 
involved. Many of the solutes affecting metabolism 
have retention and elimination characteristics that 
differ from those of current markers like urea and 
creatinine. Classic approaches to the evaluation of 
toxin retention and removal are in part inaccurate. 
Fractionation of uremic biological fluids by HPLC 
methods adds new technological possibilities for the 
better definition of the uremic syndrome. Accurate 
prevention of morbidity and mortality can only be 
pursued when this multifactorial etiologic nature of 
the uremic syndrome is taken into account. Our data 
encourage pursuit of better elimination of organic 
acid and lipophilic compounds and of the purines, 
which are groups of compounds that are currently 
disregarded in the definition of uremia. In addition, 
it should be stressed that dialysis treatment, al- 
though by definition life-saving, may exert its own 
toxicity, which can be avoided by the use of specific 
“biocompatible” membrane types. Treatment with 
drugs (allopurinol, erythropoietin) is another alter- 
native to cope with some of these problems. 
The consideration of these factors should improve 
the survival and quality of life of the patient with 
end-stage renal failure. 
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